U.S. FDA grants full approval of VITRAKVI – LUNGevity Foundation
LUNGevity Foundation shared a post on LinkedIn:
“U.S. FDA Grants Full Approval of VITRAKVI (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors. First granted accelerated approval in 2018, the full approval of VITRAKI demonstrates a clinically meaningful and durable response across a range of NTRK fusion-positive solid tumors.
‘The full approval of VITRAKVI by the FDA is a welcome step forward, solidifying its place as a treatment option for patients with NTRK gene fusion-positive cancers.
This milestone not only benefits patients today but also paves the way for further advancements in NTRK gene therapies in the future.’ said Andrea Ferris, President and CEO, LUNGevity Foundation.
Learn more about this approval.”
More posts featuring LUNGevity Foundation.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023